GlassScriptPhysician profile
Marco Rosario Corallo
NPI 1568550549
$175,087.96
in general payments reported to CMS, 2019-2025
46 companies · $2,822 in 2025
The $2,822 reported for 2025 was more than what 82% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $34K · 2021: $35K · 2022: $30K · 2023: $7,307 · 2024: $38.14 · 2025: $2,822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,637 · Food and Beverage: $2,446 · Travel and Lodging: $72.10 · Education: $12.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,636.50 |
| Food and Beverage | $2,446.26 |
| Travel and Lodging | $72.10 |
| Education | $12.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $73,761.25 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $33,445.50 | 2019-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $21,359.09 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17,897.75 | 2019-2023 | Tradjenta, Jardiance, Synjardy |
| Lilly USA, LLC | $10,700.17 | 2019-2025 | Mounjaro, Jardiance, Lyumjev |
| Esperion Therapeutics, INC. | $5,827.34 | 2020-2025 | Nexletol |
| Corcept Therapeutics | $3,638.24 | 2019-2025 | Korlym |
| Merck Sharp & Dohme LLC | $2,351.65 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,202.26 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $836.61 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $666.68 | 2019-2022 | |
| Abbvie INC. | $611.34 | 2019-2023 | Synthroid |
| Novartis Pharmaceuticals Corporation | $241.37 | 2022-2025 | |
| Medtronic, INC. | $230.30 | 2021-2025 | Inpen Smart Insulin Delivery System |
| Xeris Pharmaceuticals, INC. | $199.52 | 2021-2023 | Gvoke Hypopen, Recorlev |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marco Corallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.